Oct 20, 2025 8:30 am EDT Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs
Oct 13, 2025 7:30 am EDT Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program
Oct 8, 2025 7:30 am EDT Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy
Oct 1, 2025 7:30 am EDT Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 2, 2025 7:30 am EDT Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 29, 2025 7:30 am EDT Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
Aug 14, 2025 7:30 am EDT Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
Aug 1, 2025 7:30 am EDT Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 15, 2025 7:30 am EDT ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
Jul 2, 2025 7:30 am EDT Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million
